VIDO Expands Animal Disease Research with 3 Scientists Focused on H5N1, African Swine Fever and Swine Immunity

Saskatchewan strengthens its position in livestock vaccine research as Canada intensifies preparedness for high-impact animal diseases

The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has recruited three internationally experienced scientists to strengthen its research capabilities in emerging influenza, livestock vaccines and swine immunology. Announced on 1 October 2026, the appointments reinforce VIDO’s focus on developing next-generation vaccines and addressing infectious diseases with significant implications for livestock production, food security and public health.

The appointments bring expertise in three strategically important areas: highly pathogenic avian influenza (H5N1), African swine fever (ASF), and porcine immune responses.

Three specialists, three critical research priorities

Dr. Troy Sutton — Emerging influenza and H5N1

Dr. Sutton joined VIDO in July 2026, returning to Canada after nearly a decade at Pennsylvania State University. His research focuses on emerging influenza viruses, including H5N1, examining viral transmission, disease mechanisms, animal and human health risks, and vaccine development.

H5N1 has expanded beyond traditional poultry-associated concerns, with infections in US dairy cattle raising additional questions about interspecies transmission, surveillance and control.

Dr. Anna Lacasta — African swine fever and livestock vaccines

Dr. Lacasta joined VIDO in July 2026 from the International Livestock Research Institute in Kenya, where she led vaccine research on ASF and East Coast fever.

Her research at VIDO will concentrate on developing safer and more effective vaccines for ASF and other livestock diseases. ASF remains a major threat to the global pig industry because of its high economic impact, rapid spread and lack of widely available commercial vaccines.

Dr. Leonie Bettin — Porcine immunity and mucosal protection

Dr. Bettin joined in September 2026 after completing postdoctoral research at the University of Veterinary Medicine Vienna.

A veterinarian and immunologist, she studies porcine T-cell biology and mucosal immunity. Her work aims to improve understanding of how pigs respond to infection and vaccination, potentially informing more effective vaccine design and evaluation.

Economic exposure underscores the importance of vaccine innovation

The University of Saskatchewan cited estimates from a recent Canadian economic-impact study to illustrate the potential value of disease prevention.

These figures represent estimated economic losses that effective vaccines could potentially help avert during outbreaks. They are not realized savings or forecasts of vaccine-market revenue.

Industry implications

VIDO’s expanded research capacity is strategically relevant to the animal-health industry in three ways.

First, the development of effective ASF vaccines could transform swine disease management, reducing the economic exposure associated with outbreaks, trade restrictions and herd losses.

Second, the evolving epidemiology of H5N1 increases demand for integrated surveillance, diagnostics, biosecurity and vaccine technologies across poultry and dairy production.

Third, improved understanding of porcine immunity could support the development of more targeted vaccines, potentially improving protection and vaccination strategies in commercial swine production.

VIDO already operates high-containment laboratories, large-animal research infrastructure and GMP-compliant vaccine manufacturing capabilities. Its combination of research and translational infrastructure provides a platform for moving promising discoveries towards practical applications.

For animal-health companies, vaccine developers and livestock-sector investors, VIDO’s appointments are an indicator of continued investment in infectious-disease preparedness rather than an announcement of immediately commercializable products.

The central industry takeaway: The growing economic stakes of H5N1 and ASF are reinforcing the strategic importance of vaccine research, advanced immunology and collaborative disease-prevention infrastructure.